ARNA
NASDAQArena Pharmaceuticals Inc.
News · 26 weeks10%
2025-12-142026-06-07
Mix190d
- Leadership1(100%)
Latest news
25 items- PRSensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual ReportGJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing; six-month efficacy data expected in Q1 2026 Strengthened balance sheet and shareholder registry via €60m financing in January 2026, including a €20m strategic investment from Sanofi; cash runway extended to end of H1 2027 Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2025 results, provided a corp
- PRSensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year ReportAchieved expedited enrollment completion of first two Cohorts in Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company's gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene Positive initial safety profile reported in all six patients treated so far Data from Cohort 1, at the minimally effective dose, demonstrate early signs of hearing improvement in Patient 3, using a range of standard hearing tests Data from Cohort 2, at a higher dose, are currently being gathered; Data Monitoring Committee expected by the end of H2 2025 GJB2-GT on track for first CTA filing in Q1 2026; Regulato
- PRSensorion Strengthens Leadership Team with Appointment of Amit Munshi as Chairman of the Board and Independent DirectorRegulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Amit Munshi, as Sensorion's independent director and Chairman of the Board, effective April 1, 2025. Mr. Munshi succeeds Mr. John Furey who stepped down as an Independent Board Member. Mr. Munshi is then appointed Chairman of the Board, replacing Khalil Barrage who served as the Company's interim Chairman since March 31, 2023. Mr. Barrage will continue to serve as a director on Sensorion's Board. This appointment by the Board of directors is performed b
- SECSEC Form 15-12G filed by Arena Pharmaceuticals Inc.15-12G - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
- SECSEC Form EFFECT filed by Arena Pharmaceuticals Inc.EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
- SECSEC Form EFFECT filed by Arena Pharmaceuticals Inc.EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
- SECSEC Form EFFECT filed by Arena Pharmaceuticals Inc.EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
- SECSEC Form EFFECT filed by Arena Pharmaceuticals Inc.EFFECT - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
- INSIDERSEC Form 4: Nova Tina Susan disposed of 20,843 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Fetzer Oliver disposed of 9,692 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Knobil Katharine disposed of 6,821 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Gallahue Kieran disposed of 12,911 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Jarrett Jennifer disposed of 11,217 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Neil Garry Arthur disposed of 11,217 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Schoch Steven J disposed of 4,600 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Ouzren Nawal disposed of 4,555 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Dallas Jayson Donald Alexander disposed of 7,152 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Munshi Amit disposed of 114,897 shares and gifted 10,500 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Manion Douglas J. disposed of 36,462 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Stelzer Laurie disposed of 37,208 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Schmidt Joan disposed of 36,287 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Aurentz Vincent disposed of 55,964 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- INSIDERSEC Form 4: Lisicki Robert disposed of 37,563 shares, closing all direct ownership in the company4 - ARENA PHARMACEUTICALS INC (0001080709) (Issuer)
- SECSEC Form POSASR filed by Arena Pharmaceuticals Inc.POSASR - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
- SECSEC Form POS AM filed by Arena Pharmaceuticals Inc.POS AM - ARENA PHARMACEUTICALS INC (0001080709) (Filer)
ARNA FAQ
7 questionsWhat does Arena Pharmaceuticals Inc. do?
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with...Where does ARNA stock trade?
Arena Pharmaceuticals Inc. (ARNA) is listed on NASDAQ.What sector and industry is ARNA in?
Arena Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arena Pharmaceuticals Inc. go public?
Arena Pharmaceuticals Inc. (ARNA) completed its IPO in 2000.What are analysts saying about ARNA?
Arena Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Neutral on 2022-02-09.What companies are similar to ARNA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ARNA side-by-side with any of them on Quantisnow.How can I track ARNA on Quantisnow?
Quantisnow aggregates Arena Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARNA to receive live email and push alerts on every new disclosure.